Cet anticorps anti-TNF alpha (Infliximab Biosimilar) est un anticorps Monoclonal produit chez le Souris, détectant TNF alpha (Infliximab Biosimilar) dans FACS et in vivo. Convient pour Humain.
The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
Attributs du produit
Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell. Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction. Syd Labs also provides the following anti-TNF antibody biosimilar protein:
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method
Immunogène
The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.
Restrictions
For Research Use only
Format
Liquid
Concentration
> 3 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Stock
4°C,-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.